Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

NCT01177683 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

32

Enrollment

OTHER

Sponsor class

Stopped Lack of accrual

Conditions

Multiple Myeloma

Interventions

DRUG: Bendamustine
DRUG: Doxorubicin
DRUG: Bortezomib
DRUG: Bendamustine
DRUG: Filgrastim

Sponsor

Sherif Farag, MB, BS

Collaborators

[object Object]
[object Object]